ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
6,040.34
-0.11%
US Tech 100
20,605.20
-0.03%
Dow Jones
44,685.57
-0.22%
Brent Oil
73.71
2.53%
Bitcoin
95,330.36
-0.56%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NYSE

  6. Arcus Biosciences Inc (RCUS) Quote

Arcus Biosciences Inc

Arcus Biosciences Inc (RCUS)

NYSE
16.30
0.36
( 2.26% )
Updated: 12:05:42
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
16.30
Bid
-
Ask
-
Volume
176,926
15.63 Day's Range 16.47
13.52 52 Week Range 20.31
Market Cap
1.492B
Previous Close
15.94
Open
15.90
Last Trade
2
@
16.33
Last Trade Time
12:06:04
Financial Volume
$ 2,852,392
VWAP
16.1219
Average Volume (3m)
726,959
Shares Outstanding
91,511,609
Dividend Yield
-
PE Ratio
-4.86
Earnings Per Share (EPS)
-3.35
Revenue
117M
Net Profit
-307M

About Arcus Biosciences Inc

Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule... Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB680, and Zimberelimab. Arcus conducts clinical trials for different types of cancers such as Prostate, Lung, Colorectal, Pancreatic, and others. The company operates through the single segment being the business of developing and commercializing immunotherapies. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.arcusbio.com
Headquarters
Camden, Delaware, USA
Founded
-
Arcus Biosciences Inc is listed in the Pharmaceutical Preparations sector of the New York Stock Exchange with ticker RCUS. The last closing price for Arcus Biosciences was $15.94. Over the last year, Arcus Biosciences shares have traded in a share price range of $ 13.52 to $ 20.31.

Arcus Biosciences currently has 91,511,609 shares outstanding. The market capitalization of Arcus Biosciences is $1.46 billion. Arcus Biosciences has a price to earnings ratio (PE ratio) of -4.86.

Ask ADVFN Intelligence (AI)

RCUS Latest News

More News

Arcus Biosciences to Participate in Two Upcoming Investor Conferences

Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that...

November 19 2024
Business Wire

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today...

November 12 2024
Business Wire

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

November 08 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

November 06 2024
Edgar (US Regulatory)

Form 8-K - Current report

November 06 2024
Edgar (US Regulatory)

Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline Update

Data from the Phase 1/1b ARC-20 study of casdatifan were presented at an oral plenary session at the 2024 EORTC-NCI-AACR Symposium; a low rate of primary progression (19%) and promising...

November 06 2024
Business Wire

Arcus Biosciences Announces that Domvanalimab Plus Zimberelimab Improved Overall Survival in ARC-10, a Randomized Study in Patients with PD-L1-High Non-Small Cell Lung Cancer

Domvanalimab plus zimberelimab was associated with greater progression-free survival, overall survival, and objective response rate compared with those of zimberelimab or chemotherapy A 36...

November 05 2024
Business Wire

Arcus Biosciences to Present New Data for Anti-TIGIT Domvanalimab Plus Zimberelimab at the Society for Immunotherapy of Cancer Annual Meeting

Data, including overall survival, from ARC-10, a randomized study evaluating domvanalimab plus zimberelimab in front-line, PD-L1-high, locally advanced or metastatic non-small cell lung cancer...

October 30 2024
Business Wire

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today...

October 24 2024
Business Wire

Form 8-K - Current report

October 24 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
12.0114.065780265914.2916.614.2963579815.78435435CS
40.85.1612903225815.518.9814.1577833315.91466044CS
120.10.61728395061716.218.9814.1572695916.50367054CS
260.483.0341340075915.8218.9813.5270304316.15346982CS
520.261.6209476309216.0420.3113.5273573016.63668831CS
156-29.29-64.24654529545.594712.9587066222.03401043CS
2608.46107.9081632657.8449.17.6974075723.85148022CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
PSQHPSQ Holdings Inc
$ 3.9185
(90.22%)
74.93M
ATIPATI Physical Therapy Inc
$ 2.1756
(29.50%)
2.51M
LEVLion Electric Company
$ 0.3414
(18.95%)
23.78M
BBAIBigBear ai Holdings Inc
$ 2.6079
(18.54%)
27M
CNMCore and Main Inc
$ 55.7002
(15.35%)
4.53M
TCSContainer Store Group Inc
$ 2.00
(-21.57%)
152.15k
MPLNChurchill Capital Corp III
$ 6.88
(-13.68%)
61.39k
CANGCango Inc
$ 4.08
(-13.19%)
675.91k
NOTEFiscaNote Holdings Inc
$ 0.9402
(-10.46%)
526.19k
ADCTADC Therapeutics SA
$ 2.085
(-10.13%)
212.32k
PSQHPSQ Holdings Inc
$ 3.9198
(90.28%)
75.41M
NIONIO Inc
$ 4.7519
(8.00%)
43.77M
ACHRArcher Aviation Inc
$ 6.895
(-5.55%)
35.55M
PCGPG&E Corporation
$ 20.83
(1.36%)
33.95M
TAT&T Inc
$ 23.66
(4.23%)
30.75M

RCUS Discussion

View Posts
Monksdream Monksdream 3 months ago
RCUS a buy under $14
👍️0
PennyWorld PennyWorld 1 year ago
https://seekingalpha.com/news/4005456-roche-send-anti-tigit-developers-higher-after-cancer-drug-data?ref=biztoc.com
👍️0
conix conix 3 years ago
Biotechs are starting to react to news...finally.
👍️0
dinogreeves dinogreeves 5 years ago
The stock didn't react as well as expected with the partnership, but it did hi almost my price target. This is a partnership 200 million equity investment and 175 million up front payment, which. implies no offering on the table. Makes you wonder why the stock is down, guess people were expecting a buyout. Some of these people are so lame, unbelievable.
👍️0
lovetc lovetc 5 years ago
Also in the DEF 14.....didnt see any information regarding Gilead....
👍️0
lovetc lovetc 5 years ago
shorted some and bought some put at $31 last Friday....Also today when it reached $30 I short.....I find no reason not to short above $30 lol....It will be $18 soon since the Volumn start declined....
👍️0
dinogreeves dinogreeves 5 years ago
RCUS will likely hit 40 this week and if it does that could essentially mean that there is buyout looming from GI*LD. Someone is buying heavy between 27-29 dollars, obviously they don't want it dip more than 26-27 dollars, it could be a number of reasons that is beyond any retails control.
👍️0
dinogreeves dinogreeves 5 years ago
Bought another 1000 shares on that dip, going to wait this one.
👍️0
dinogreeves dinogreeves 5 years ago
Possible huge asset buy, or outright buyout coming from GILD or even a partnership.
👍️0
dinogreeves dinogreeves 5 years ago
RCUS getting ready to pop to 33-35 dollars.
👍️0
dinogreeves dinogreeves 5 years ago
This is my letter to the shorts with margin account


That is where dummies like you are mistaken. If GILD places anywhere close to that dollar amount this stock jumps over triple digits in less then 2 hours and if there is buyout it won't even let you blink, just one share will it to the buyout price. If GOOGLE has 17% stake on this company and GILD is looking to either buy or take a stake, there must be something that you and I are not aware of the current directors sold their pervious company to Bristol for 1.5 billion dollars. There is more here than meets the eye. I am taking my chance because if no balls no glory and when that happens short margin account will be vaporized.


https://markets.businessinsider.com/news/stocks/arcus-biosciences-stock-spikes-reports-gilead-investing-cancer-drug-biotech-2020-4-1029100118
👍️0
dinogreeves dinogreeves 5 years ago
If this happens the stock will shoot up to over $200 dollars in an instant. Only if that happens.



https://markets.businessinsider.com/news/stocks/arcus-biosciences-stock-spikes-reports-gilead-investing-cancer-drug-biotech-2020-4-1029100118
👍️0
dinogreeves dinogreeves 5 years ago
News could come from GI*LD that there is a buyout. Watch for news.
👍️0

Your Recent History

NYSE
RCUS
Arcus Biosciences
NASDAQ
GOOG
Alphabet
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved